Jeppe Øvli Øvlesen is a seasoned executive in the medtech, biotech, and IT healthcare sectors.

He has played pivotal roles as founder, CEO, chairman, and board member in numerous successful companies, including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Perfusion Tech, Resother Pharma, PNN Medical, Cereno Scientific, and TXP Pharma. Since 2015, Jeppe has served as the CEO of Synact Pharma, leading the company to go public on Spotlight and later uplisting to Nasdaq Stockholm.

Jeppe holds an MBA from the University of Hartford in the United States.

Marit Salte is, since March 2024, CEO of the Smedvig Family Office (SFO).

Prior to that and since 2005, she was CFO of the Smedvig Family Office (SFO). She was also CFO and Compliance Officer for Smedvig Investment Management AS (SIM) from 2007 to 2012, contributing to establishing SIM as an investment manager regulated by the Norwegian FSA. Between 2002 and 2005, she was Finance Manager for Smedvig. She holds several board positions in companies within the Smedvig Family Office and in companies where Smedvig has invested, both in the UK, Denmark, and Norway.

Marit Salte has been a member of the Board of Statkraft from 2020 until June 2024. Statkraft is owned by the Norwegian state and is Europe’s largest supplier of renewable energy and a global company in energy market operations. Earlier board positions include Green Mountain (datacenter business sold to Azrieli in 2021), Navtor (e-navigation business sold to AKKR in 2020), and DSD (Stavanger-based family office with large investments in mobility and health care). Current Board positions include Ydalir Foundation (Chair from July 2023), Veni AS (It & Tech) and a role as an Investment Advisor for Sparebankstiftelsen SR-Bank, a foundation holding a large ownership position in one of Norway’s largest banks.

The Smedvig Family Office has offices in Stavanger and London with total assets under management of over USD 2 billion.

Ulla Bagger-Sørensen is a strategic innovator with over 25 years of experience in the tech industry, particularly in leadership, sales, and innovation across small, medium, and global enterprises.

As the CIO at Bagger-Sørensen, she is leading pioneering initiatives like the AI Innovation House in DANDY Business Park.

Ulla Bagger-Sørensen has held key positions such as Director at CGI Denmark and COO of AI Innovation House. She also serves on the boards of Bagger-Sørensen Foundation and Rosborg Gymnasium.

Ulla holds a Cand. Merc. in International Business from Aarhus University and has completed various executive education programs.

Jonathan Lerner is a partner at Smedvig Ventures with over sixteen years’ experience investing in and supporting high-growth technology businesses.

He is currently a board member of Semble, Masabi, Poq, and Infinity and has previously served on the boards of Captify, The Smart Cube, and Tusker. Prior to Smedvig, Jon worked at Bain & Company as a Senior Consultant in London and Toronto.

He also spent 6 months working in-house at Argos on multi-channel strategy and product expansion.

Mikkel Bo Hansen entered the field of Neuroscience and Neuroimaging in autumn 2011, coming from the field of quantum chemistry/physics.

Mikkel is heading the scientific and regulatory areas in Cercare Medical, so far resulting in full MDR clearance of five products under class IIa/IIb, multiple FDA clearances, and clearances in many other jurisdictions.

In addition, Mikkel has been instrumental in attracting more than 3m EUR in non-diluting/non-repayable funding from primarily EU instruments.

He has published more than 40 scientific papers, including Brain and Nature Communications. Mikkel is one of the key early developers of the Cercare Medical software.

Belinda has enjoyed a successful and wide-ranging investment banking career advising major institutional clients and companies in senior roles at Merrill Lynch, HSBC and Deutsche Bank.

In venture capital, she is operating partner at TSP Ventures and has advised early-stage companies across agtech, medtech and clean energy. Belinda is a former non-executive director of Canadian hydrogen company Proton H2 and is currently chairman of the supervisory board at Path2 Hydrogen AG which is listed on Deutsche Borse.